Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT07462260
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 100 participants
- Sponsor
- Sindh Institute of Cardiovascular Diseases
- Registry
-
NCT07462260
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Pakistan
- Registry status
- Completed
Technical summary
Registry record NCT07462260. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-01 (actual); primary completion 2026-09-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)
- Acronym
- SERIES
- Condition
- Pulmonary Hypertension
- Condition
- Rheumatic Valvular Heart Disease
- Intervention (Drug)
- Sildenafil 25 MG
- Intervention (Drug)
- Placebo
- Lead sponsor
- Sindh Institute of Cardiovascular Diseases
- Collaborator
- National Institute of Cardiovascular Diseases
Record details
- Record id
cardio:ct-nct07462260- Content hash
e4d39928d281e57ab892aecd3a38932feab25847ccdf6a9ca5eb2e658e42be19